Syndax Pharmaceuticals, Inc. (SNDX) Analysts See $-0.94 EPS; Jaffray Companies Piper (PJC) Has 1.23 Sentiment

April 12, 2018 - By Marie Mckinney

Piper Jaffray Companies (NYSE:PJC) Logo

Analysts expect Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to report $-0.94 EPS on May, 14.They anticipate $0.23 EPS change or 32.39% from last quarter’s $-0.71 EPS. After having $-0.80 EPS previously, Syndax Pharmaceuticals, Inc.’s analysts see 17.50% EPS growth. The stock decreased 1.50% or $0.17 during the last trading session, reaching $11.16. About 243,319 shares traded. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has risen 7.53% since April 12, 2017 and is uptrending. It has underperformed by 4.02% the S&P500.

Jaffray Companies Piper (PJC) investors sentiment increased to 1.23 in Q4 2017. It’s up 0.14, from 1.09 in 2017Q3. The ratio improved, as 86 institutional investors increased or opened new stock positions, while 70 sold and decreased their positions in Jaffray Companies Piper. The institutional investors in our database reported: 10.36 million shares, up from 9.99 million shares in 2017Q3. Also, the number of institutional investors holding Jaffray Companies Piper in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 22 Reduced: 48 Increased: 44 New Position: 42.

The stock increased 1.55% or $1.25 during the last trading session, reaching $82.15. About 31,638 shares traded. Piper Jaffray Companies (PJC) has risen 30.55% since April 12, 2017 and is uptrending. It has outperformed by 19.00% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 2 sales for $5.63 million activity.

Matarin Capital Management Llc holds 0.9% of its portfolio in Piper Jaffray Companies for 134,155 shares. Greenwich Wealth Management Llc owns 58,472 shares or 0.84% of their US portfolio. Moreover, Hwg Holdings Lp has 0.63% invested in the company for 8,683 shares. The New Jersey-based Systematic Financial Management Lp has invested 0.32% in the stock. Kennedy Capital Management Inc., a Missouri-based fund reported 203,810 shares.

Piper Jaffray Companies operates as an investment bank and asset management firm that serves firms, private equity groups, public entities, non-profit entities, and institutional investors in the United States and internationally. The company has market cap of $1.25 billion. The companyÂ’s Capital Markets segment offers investment banking and institutional sales, trading, and research services for various equity and fixed income products. It currently has negative earnings. It raises capital through equity financings; provides advisory services relating to mergers and acquisitions, equity private placements, and debt advisory services for corporate clients; underwrites debt issuances; and offers municipal financial advisory and loan placement services, as well as various over-the-counter derivative products.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company has market cap of $275.63 million. The company's lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It currently has negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

Piper Jaffray Companies (NYSE:PJC) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>